Budget impact of nimotuzumab plus chemoradiotherapy in patients with advanced head and neck cancer
Abstract
Introduction: The oncological drugs developed recently, including biological therapies, have a huge economic impact on health care systems.
Objective: Estimate the budget impact of incorporating nimotuzumab for the treatment of patients with squamous head and neck cancer at advanced stages in the National Health System.
Methods: A budget impact model was developed to compare two schemes with different nimotuzumab therapy regimens (future scenario) combined with chemoradiotherapy (current scenario) in a five-year time period. The costs avoided and the number of patients potentially affected were measured with epidemiological data from the National Cancer Registry. A 20% penetration rate was assumed annually until 100% would be reached at the fifth year. Univariate deterministic sensitivity analysis was performed, taking as base case the mean annual budget impact value obtained.
Results: Maximum budget impact at the fifth year with scheme A was 83 million and decreased significantly to 24 million with scheme B. Mean avoided cost is 33 362 718.08 million Cuban pesos. According to the sensitivity analysis performed, with nimotuzumab price variations of ±5-10% and a target population of ± 20%, the target population change is most influential on the base case.
Conclusions: Addition of nimotuzumab to chemoradiotherapy in shorter administration regimens is more efficient and its impact on budget is lower, leading to greater sustainability by the National Health System.
Key words: nimotuzumab, head and neck cancer, budget impact analysis, costs.
Downloads
References
1. Sung H, Ferlay J, Siegel RL, Laverssane M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN Estimate of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3):209-49. DOI: http://dx.doi.org/10.3322/caac.21660.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: http://dx.doi.org/10.3322/caac.21492.
3. Ministerio de Salud Pública. Anuario Estadístico de Cuba 2019. MINSAP, Dirección Nacional de Registros Médicos y Estadísticas de Salud: La Habana. 2020 [acceso 30/05/2021]. Disponible en: https://files.sld.cu/bvscuba/files/2020/05/AnuarioElectrónico-Español-2019-ed-2020.pdf
4. Galán Y, Iglesias Y, Kindelan G, Planas S, Fernandez LM. Incidencia de cáncer en Cuba en el 2016. Rev Cub Oncol. 2020;18(3): e_46. Disponible en: http://revoncologia.sld.cu/index.php/onc/article/view/46/36
5. ACTION Study Group, Jan S, Kimman M, Peters SA, Woodward M. Financial catastrophe, treatment discontinuation and death associated with surgically operable cancer in South-East Asia: Results from the ACTION Study. Surgery. 2015; 157(6):971-982. DOI: http://dx.doi.org/10.1016/j.surg.2015.02.012.
6. Patterson RH, Fischman VG, Wasserman I, Siu J, Shrime MG, Fagan JJ, et al. Global burden of head and neck cancer: economic consequences, health, and the role of surgery. Otolaryngol Head Neck Surg. 2020; 162(3):296-303. DOI: http://dx.doi.org/10.1177/0194599819897265.
7. Prasad V, Wang RB, Afifi SH, Mailankody S. The rising price of cancer drugs-a new old problem? JAMA Oncol. 2017; 3(2):277-278. DOI: http://dx.doi.org/10.1001/jamaoncol.2016.4275.
8. Van de Vooren K, Duranti S, Curto A, Garattini L. A critical systematic review of budget impact analyses on drugs in the EU countries. Appl Health Econ Health Policy. 2014; 12:33-40. DOI: http://dx.doi.org/10.1007/s40258-013-0064-7.
9. Faleiros DR, Alvare J, Almeida AM, Eloisa de Araujo V, Andrade EIG, Godman B, et al. Budget impact analysis of medicines: updated systematic review and implications. Expert Rev Pharmacoecon Outcomes Res. 2016; 16(2):257-266. DOI: http://dx.doi.org/10.1586/14737167.2016.1159958.
10. Godman B, Bucsics A, Vella Bonanno P, Oortwijn W, Rothe CC, Ferrario A, et al. Barriers for access to new medicines: searching for the balance between rising costs and limited budgets. Front Publ Health. 2018; 6:328. DOI: http://dx.doi.org/10.3389/fpubh.2018.00328.
11. Saúrez G, Bencomo A. Nimotuzumab, inmunoterapia eficaz para el tratamiento de tumores epiteliales malignos. Biotecnología Aplicada. 2014; 31:150-158.
12. Osorio M, Cruz T, del Castillo R, Roca C, Azcue M, Neninger E, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther. 2010; 9(5):343-349. DOI: http://dx.doi.org/10.4161/cbt.9.5.10981.
13. Basavaraj C, Sierra P, Shivu J. Nimotuzumab with chemoradiation confers a survival advantage in treatment-naive head and neck tumors over expressing EGFR. Cancer Biol Ther. 2010; 10(7):673-681. DOI: http://dx.doi.org/10.4161/cbt.10.7.12793.
14. Centro Estatal para el Control de Medicamentos (CECMED). Nimotuzumab. Resumen de las características del producto. [acceso 30/05/2021]. Disponible en: https://www.cecmed.cu/registro/rcp/cimaherr-nimotuzumab.
15. Colectivo de autores. Formulario Nacional de Medicamentos. En: Calvo Barbado DM, Delgado Martínez I, editores. Formulario nacional de medicamentos. 4th ed. La Habana: ECIMED; 2014.
16. Patil VM, Noronha V, Joshi A, Agarwal J, Ghosh-Laskar S, Budrukkar A, et al. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer. Cancer. 2019;125(18):3184-3197. DOI: http://dx.doi.org/10.1002/cncr.32179.
17. Consejo de Salubridad General. Guía para la Conducción de Estudios de Evaluación Económica para la Actualización del Cuadro Básico y Catálogo de Insumos del Sector Salud en México [Internet]. México DF: Dirección General Adjunta de Priorización; 2017. Disponible en: http://www.csg.gob.mx/descargas/pdf/priorizacion/cuadro-basico/guias/conduccion_estudios/GCEEE_2017_Diciembre_x1x.pdf (Actualizado: diciembre de 2017; Consultado en línea: 23 de mayo de 2021).
18. Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014; 17(1):5-14. DOI: http://dx.doi.org/10.1016/j.jval.2013.08.2291.
19. Mauskopf J, Earnshaw SR, Brogan A, Wolowacz S, Brodtkorb TH. Budget-Impact Analysis of Health Care Interventions. A practical guide. Cham, Switzerland: Springer International Publishing AG; 2017.
20. Viada C, Vega AM, Robaina M, Frías A, Álvarez M, Santiesteban Y, et al. Evaluación de Nimotuzumab para el tratamiento de cáncer de cabeza y cuello: Meta-análisis de ensayos controlados. Rev Bionatura. 2020; 5(1):1056-1062. DOI: http://dx.doi.org/10.21931/RB/2020.05.01.8.
21. Crombet-Ramos T, Mestre-Fernández B, Mazorra-Herrera Z, Iznaga-Escobar N. Nimotuzumab for patients with inoperable cancer of the head and neck. Front Oncol. 2020; 10:817. DOI: http://dx.doi.org/10.3389/fonc.2020.00817.
22. Vega A, Vila L, Venereo P, Valls A, De Armas E, Romero M, et al. Safety and effectiveness of nimotuzumab in the treatment of advanced head and neck cancer patients. Phase IV clinical trial: final results. JJ Cancer Sci Res. (2019) 4:057.
23. Ang KK, ZhangQ, RosenthalDI,Nguyen-Tan PF, Sherman EJ,Weber RS, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. (2014) 32:2940–50. DOI: http://dx.doi.org/10.1200/JCO.2013.53.5633.
24. Mesía R, Henke M, Fortin A, Minn H, Yunes Ancona AC, Cmelak A, et al. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. (2015) 16:208–20. DOI: http://dx.doi.org/10.1016/S1470-2045(14)71198-2.
25. Puig J, Oliva J, Trapero M, Abellán JM, Brosa M. Guía y recomendaciones para la realización y presentación de evaluaciones económicas y análisis de impacto presupuestario de medicamentos en el ámbito del CatSalut [Internet]. Barcelona: Departament de Salut. Servei Catal? de la Salut; 2014. Disponible en: http://catsalut.gencat.cat/web/.content/minisite/catsalut/proveidors_professionals/medicaments_farmacia/farmaeconomica/caeip/documents/gaeip_publica_castellano_octubre2014_catsalut.pdf (Actualizado 2014; Consultado en línea: 10 de mayo de 2021).
26. Koramati SL, Sarathy V, Varayathu H, Thomas BE, Naik R. Addition of Nimotuzumab to standard TPF regimen in locally advanced head and neck cancer: a single institutional study. J Oncol. 2021;2021:6641963. DOI: https://doi.org/10.1155/2021/6641963.
27. Mohamed A, Twardy B, Zordok MA, Ashraf K, Alkhoder A, Schrapp K, et al. Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: comparative analysis. Head Neck. 2019; 41:1490-1498. DOI: http://dx.doi.org/10.1002/hed.25379.
28. Szturz P, Wouters K, Kiyota N, Tahara M, Prabhash K, Noronha V, et al. Low-Dose vs. high-dose cisplatin: lessons learned from 59 chemoradiotherapy trials in head and neck cancer. Front Oncol. 2019; 9:86. DOI: http://dx.doi.org/10.3389/fonc.2019.00086.
Downloads
Published
How to Cite
Issue
Section
License
Esta revista provee acceso libre e inmediato a su contenido bajo el principio de que hacer disponible gratuitamente la investigación al público apoya a un mayor intercambio de conocimiento global.
Esto significa que se permite su copia y distribución por cualquier medio siempre que mantenga el reconocimiento de sus autores, no haga uso comercial de las obras y no realice ninguna modificación de ellas.
El envío de manuscritos, el procesamiento y la publicación no ofrece ningún coste a los autores, es totalmente gratis.
